On Friday, Shares of Sunedison Inc (NYSE:SUNE), lost -6.34% to $8.49.
Equinix, Inc. (EQIX), the global interconnection and data center company, recently declared that it has signed a power purchase agreement (PPA) for 105 megawatts (MWAC) of new solar power with SunEdison, Inc. (SUNE), the largest global renewable energy development company. This purchase will cover all of Equinix’s California data centers, counting 11 facilities located in the Los Angeles and Silicon Valley metro areas, in addition to its Redwood City, California global headquarters. With this deployment, Equinix’s data center footprint will improvement its use of clean, renewable sources from 30% to 43% globally.
Highlights / Key Facts
- The project, known as the Mount Signal Solar II project, will be located in the territory of San Diego Gas & Electric near Calexico, California, and just north of the United States-Mexico border. Construction of the 150 MWAC total capacity solar farm is predictable to start in 2015 and achieve commercial operation in the second half of 2016.
- The Mount Signal Solar II project is predictable to generate 300,000 MWh per year to offset Equinix’s electrical consumption. The project will effectively reduce Equinix’s carbon footprint by over 180 million lbs of CO2 annually – the equivalent of taking 18,000 passenger cars off of U.S. roads each year [1]. Equinix will also receive Green-e certified renewable energy certificates from SunEdison to bridge the about 12 months from contract execution to project completion.
- Earlier this year Equinix declared its commitment to 100 percent clean and renewable energy for its entire global footprint of 105 data centers located in 33 markets. Through ongoing development of partnerships Equinix continues to deploy innovative new technologies to make this commitment a reality. Most recently it deployed a 342 kWp PV solar system at its SG3 International Business Exchange™ (IBX®) data center in Singapore and is in the process of installing a 1MW fuel cell system, fueled by bio-gas, at its Silicon Valley (SV5) data center.
SunEdison, Inc. (SunEdison) is a developer and seller of photovoltaic energy solutions, an owner and operator of clean power generation assets, and a developer and manufacturer of silicon wafers. The Company operates in three segments: Solar Energy, TerraForm Power and Semiconductor Materials through SunEdison Semiconductor Ltd. (SSL). The Company’s Solar Energy segment provides solar energy services that integrate the design, installation, financing, monitoring, operations and maintenance portions of the downstream solar market for the Company’s customers.
Shares of Transocean LTD (NYSE:RIG), declined -3.46% to $12.56, during its last trading session, after the oil drilling company was linked to Petrobras’ (PBR) ongoing corruption investigation.
A former Petrobras executive, Eduardo Musa, recently said he received payments from a Transocean agent in exchange for a rig operation contract, according to Bloomberg.
Petrobras temporarily blocked more than 20 suppliers from working with the state-run oil company as a result of the corruption probe into the alleged pay-to-play scheme known as Carwash. Transocean is not comprised in that list of companies.
Transocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. The Company’s primary business is to contract its drilling rigs, related equipment and work crews primarily on a day rate basis to drill oil and gas wells. The Company specializes in technically demanding regions of the global offshore drilling business with a particular focus on deepwater and harsh environment drilling services.
Shares of AbbVie Inc (NYSE:ABBV), declined -1.47% to $55.74, during its last trading session.
AbbVie declared that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
“We believe ABT-494 has the potential to become a best-in-class therapy for patients,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “In our view, ABT-494 also offers a faster path to Phase 3 development with less uncertainty.”
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, counting rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone.
Finally, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ended its last trade with -4.86% loss, and closed at $199.32.
Valeant Pharmaceuticals wholly owned partner, Bausch + Lomb, and Nicox S.A. (NYSE Euronext Paris: COX) declared that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for VESNEO(TM) (latanoprostene bunod ophthalmic solution 0.024%), an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. If approved, VESNEO will be the first nitric oxide donating prostaglandin receptor agonist available for the above indication.
Upon instillation in the eye, latanoprostene bunod is rapidly metabolized to two actives; latanoprost acid, a prostaglandin analog, and nitric oxide. Nitric oxide is an important physiological signaling molecule, which plays a key role in IOP regulation in healthy eyes. VESNEO is thought to improvement aqueous humor outflow by acting on both the uveoscleral (non-conventional) pathway via latanoprost acid, and trabecular meshwork and Schlemm’s canal (conventional pathway) via nitric oxide signaling.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
